Drug Profile
IONIS ANGPTL3Rx
Alternative Names: ISIS-ANGPTL3RxLatest Information Update: 15 Oct 2020
Price :
$50
*
At a glance
- Originator Isis Pharmaceuticals
- Developer Ionis Pharmaceuticals
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action ANGPTL3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias
Most Recent Events
- 12 Oct 2020 Akcea Therapeutics has been acquired by Ionis Pharmaceuticals
- 02 Mar 2017 Discontinued - Phase-I for Dyslipidaemias (In volunteers) in USA (unspecified route) (Ionis Pharmaceuticals pipeline, March 2017)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals